Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OKUR
- Price
- 2.37
- Stock movement down
- -0.02 (-0.73%)
- Company name
- OnKure Therapeutics, Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 34.81M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -82.85%
- 3 year return
- -55.71%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
OKUR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.71 |
| Daily high | 2.76 |
| Daily low | 2.64 |
| Daily Volume | 51K |
| All-time high | 149.30 |
| 1y analyst estimate | 30.00 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| OKUR | S&P500 | |
| Current price drop from All-time high | -98.18% | -1.46% |
| Highest price drop | -98.77% | -56.47% |
| Date of highest drop | 14 May 2025 | 9 Mar 2009 |
| Avg drop from high | -72.19% | -10.99% |
| Avg time to new high | 137 days | 12 days |
| Max time to new high | 1078 days | 1805 days |
COMPANY DETAILS
Marketcap
34.81M
Marketcap category
Small-cap
Description
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Employees
46
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner